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Candida species are known as opportunistic pathogens, and a possible cause of invasive
infections. Because of their species-specific antimycotic resistance patterns, reliable tech-
niques for their detection, quantification and identification are needed. We validated a DNA
amplification method for direct detection of Candida spp. from clinical samples, namely the
ITS2-High Resolution Melting Analysis (direct method), by comparing it with a culture and
MALDI-TOF Mass Spectrometry based method (indirect method) to establish the presence
of Candida species in three different types of clinical samples.
Materials and Methods
A total of 347 clinical samples, i.e. throat swabs, rectal swabs and vaginal swabs, were col-
lected from the gynaecology/obstetrics, intensive care and haematology wards at the Ghent
University Hospital, Belgium. For the direct method, ITS2-HRM was preceded by Nucli-
SENS easyMAG DNA extraction, directly on the clinical samples. For the indirect method,
clinical samples were cultured on Candida ID and individual colonies were identified by
MALDI-TOF.
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Results
For 83.9% of the samples there was complete concordance between both techniques, i.e.
the same Candida species were detected in 31.1% of the samples or no Candida species
were detected in 52.8% of the samples. In 16.1% of the clinical samples, discrepant results
were obtained, of which only 6.01% were considered as major discrepancies. Discrepan-
cies occurred mostly when overall numbers of Candida cells in the samples were low and/or
when multiple species were present in the sample.
Discussion
Most of the discrepancies could be decided in the advantage of the direct method. This is
due to samples in which no yeast could be cultured whereas low amounts could be detected
by the direct method and to samples in which high quantities of Candida robusta according
to ITS2-HRM were missed by culture on Candida ID agar. It remains to be decided whether
the diagnostic advantages of the direct method compensate for its disadvantages.
Introduction
The incidence and importance of invasive fungal infection, generally associated with high mor-
bidity and mortality rates [1], continue to increase among intensive care unit (ICU) patients,
with a global average ranging between 5 and 10 cases per 1000 ICU admissions. This increasing
incidence of candidemia is mainly due to the growing number of invasive methods [2,3] and
the frequent use of broad-spectrum antibiotics, leading to the suppression of bacterial coloniza-
tion and possible subsequent proliferation of pathogenic fungi [4,5]. In addition, effective anti-
fungal therapy is often started with delay due to the time consuming culture based
identification and susceptibility testing of fungi [2,3].
Candida albicans is still the most important opportunistic fungal pathogen causing infec-
tions in humans [6]. However, candidemia caused by non-albicans Candida species is increas-
ing worldwide [1]. The most prevalent non-albicans Candida species of clinical importance
include C. dubliniensis, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei [7–10]. This
increase in diversity and the associated species-dependent susceptibility to antimycotics [11]
complicate the appropriate choice of antifungal therapy. For example, almost all C. albicans
isolates are susceptible to fluconazole, a first-line antimycotic in the treatment of candidiasis.
But non-albicans species, such as C. glabrata and C. krusei, are respectively partially or totally
resistant to this antimycotic agent, with as a consequence that inappropriate therapy is contin-
ued until proper identification of the yeast becomes available. Over the past decade, echinocan-
dins are more frequently used as first-line therapy for invasive candidiasis because of their
broad-spectrum antimycotic activity. However, the emerging resistance of C. glabrata against
echinocandins has been suggested to be the result of the extensive use of echinocandins
[11,12].
These observations emphasize the importance of developing methods for rapid and accurate
species identification [13,14], especially in patients requiring intensive care [12].
Since conventional phenotypic methods are often time-consuming and their results are
sometimes ambiguous, molecular techniques for routine identification of fungi have been
developed [15–22].
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We previously optimized ITS2-High Resolution Melting curve analysis (ITS2-HRM) and
showed that this technique, applied after ITS2-qPCR, led to the unambiguous identification of
the clinically most relevant Candida species [23]. The use of ITS2-HRM enables elimination of
the additional step of electrophoresis or sequencing, increasing the speed of the technique and
rendering the assay less labor-intensive and more cost-effective compared to approaches rely-
ing on electrophoresis and/or sequencing. When applied to cultured strains, DNA extraction
can be obtained by boiling colonies, a simple and inexpensive method.
The aim of this study was to validate the ability of using ITS2-HRM for the rapid detection
and identification of the clinically most relevant Candida species, and Saccharomyces cerevisiae,
directly from clinical samples, i.e. without prior cultivation. Whereas Decat et al. (2012) started
from crude DNA extracts from cultured strains, we started from pure DNA extracts from dif-
ferent types of clinical samples. This more laborious and more expensive DNA extraction
(combining Lyticase treatment and commercial NucliSENS easyMAG DNA extraction) was
needed to remove possible inhibitory components from the clinical samples and to optimize
sensitivity of the direct approach.
We assessed the applicability of ITS2-HRM directly on clinical samples by comparing it
with culture of the samples (for isolation) and MALDI-TOFMass Spectrometry (for identifica-
tion) of the cultured yeasts, as used in the routine laboratory of the Ghent University Hospital.
Materials and Methods
Ethical approval
This procedure was approved by the Ethical Committee of the Ghent University Hospital (IRB
Protocol n° 2012/703). The consent was waived by the Ethical Committee because the research
did not influence diagnosis or treatment of the patients and because samples were anonymized.
Hence, no written or verbal consent was obtained from the patients to use their samples. More-
over, research was carried out on rests of samples, which would have otherwise been discarded.
Study set up
Fig 1 summarizes the setup of the study. A total of 347 clinical samples were screened for the
presence of Fungi (with emphasis on Candida). Once the clinical samples were collected, three
different processes were followed in order to isolate and identify the Candida species present in
the clinical samples. The indirect method, and the ITS2-HRM based confirmation method,
consisted of a joint cultivation step for isolation of yeasts followed by identification, respec-
tively with Matrix Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry
(MALDI-TOF) or ITS2-HRM. In contrast to the indirect method, the direct method did not
require prior culture. This method consisted of DNA extraction directly from the sample, com-
bining Lyticase treatment and the NucliSENS easyMAG automated system, followed by the
identification and quantification of the Candida species by means of ITS2-HRM.
Clinical samples
Clinical samples were obtained with an ESwab. The collection tube contained 1 ml of liquid
transport medium in which the entire patient sample, collected with the aid of a Nylon Flocked
Swab, was delivered. The homogenous liquid sample suspension was then used for further
analysis.
A total of 347 samples from three wards at the Ghent University Hospital, Belgium, were
included, i.e. the gynaecology/obstetrics (n = 73), intensive care (IC, n = 200) and haematology
wards (n = 74). Sample types were throat swabs (n = 111, i.e., 11 from the haematology ward
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and 100 from the IC), rectal swab (n = 163, i.e., 63 from the haematology ward and 100 from
the IC) and vaginal swabs (n = 73, all from the gynaecology/obstetrics ward).
Isolation of yeasts
In order to obtain isolated colonies for identification using MALDI-TOF (indirect method)
and ITS2-HRM (confirmation method), 10 μl of the clinical sample was cultivated on selective
‘Candida ID’medium (bioMérieux, Marcy l’Etoile, France). In the context of standardization
of this study, the agar plates were incubated under the same conditions used by the routine
Fig 1. A schematic overview of the study set up.
doi:10.1371/journal.pone.0132149.g001
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laboratory, namely 48 hours at 32°C. Isolated colonies were further processed on Sabouraud
agar (see below).
Isolation of DNA
Two DNA extraction methods were used. For cultured yeasts, a simple boiling/freezing
approach was used [23], whereas for the clinical samples, DNA was extracted by the commer-
cial NucliSENS easyMAG extraction platform.
Boiling/freezing extraction was applied on yeast colonies subcultured on Sabouraud agar
(Becton Dickinson, Erembodegem, Belgium), after initial isolation from the clinical samples on
Candida ID agar. A 10 μl inoculation loop of yeast colonies was suspended in 250 μl TE-buffer
(10 mM Tris, 100 mM EDTA, pH 8 (Sigma-Aldrich, St. Louis, MO)). This suspension was
then heated during 15 minutes at 95°C, frozen for 15 minutes at -80°C, thawed at room tem-
perature and centrifuged to pellet the cell debris. The supernatant was used as DNA extract.
Prior to the commercial DNA extraction of the clinical sample, the yeast cell wall was weak-
ened by means of Lyticase (Sigma-Aldrich) and β-mercaptoethanol (Fluka Chemie GmbH,
Buchs, Switzerland). A total of 200 μl of clinical sample was mixed with 250 μl of Lyticase Lysis
Buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 1.2 M sorbitol, 10 mM β-mercaptoethanol, 2
U Lyticase/μl) in 1.7 ml Eppendorf tubes, and incubated for 30 minutes at 37°C. After incuba-
tion, the suspension was transferred to 4 ml of NucliSENS easyMAG disposable sample vessels,
after which 1450 μl of NucliSENS easyMAG Lysis Buffer was added. During incubation for 10
minutes at room temperature, magnetic silica was mixed in equal volumes with NucliSENS
easyMAG extraction buffer 3. After the 10 min incubation period, 100 μl of magnetic silica v/v
NucliSENS easyMAG extraction buffer 3 was added to each clinical sample vial (total volume
of 2 ml), followed by the semi-automated NucliSENS easyMAG extraction protocol on the
apparatus (bioMérieux).
Matrix-Assisted Laser Desorption Ionization—Time of Flight
Mass Spectrometry. Colonies isolated from the clinical samples after 48 h of incubation at
32°C on Candida ID agar were identified by MALDI-TOF. Colonies with different colony mor-
phology were spotted onto the polished steel MALDI-TOF target plate and overlaid with
one μl of formic acid (Sigma-Aldrich) 70% (v/v) to weaken the cell wall of the yeast. After the
plate was air dried at room temperature, one μl of matrix solution, i.e. 10 mg/ml α-cyano-
4-hydroxycinnamic acid (Bruker Daltonics, Bremen, Germany) in 50% (v/v) acetonitrile/2.5%
(v/v) trifluoroacetic acid (Sigma-Aldrich), was added to each spot and the plate was again air
dried at room temperature. A bacterial test standard (BTS 255343, Bruker Daltonics) was used
as positive control and an empty well covered with matrix served as negative control. Mass
spectra were generated with a Microflex Biotyper spectrometer (Bruker Daltonics), using the
manufacturer’s standard settings. For each sample, mass fingerprints were acquired, using Bru-
ker Daltonics’ flexControl version 3.0 software, analyzed over a mass range from 2000 to
20,000 Da, and compared with the Bruker Daltonics’ database. The integrated software gener-
ated an outcome list, in which species with the most similar fingerprints were ordered accord-
ing to their logarithmic score value (log (score value)) [24]. For clinical yeast isolates, log(score
values) 1.7 were considered sufficient for secure species identification [25]. For values below
1.7, no isolate identification was possible [24].
ITS2-HRM. Each DNA extract was run in duplicate by ITS2-HRM, whereby the ITS2
region was amplified as described previously [23]. Briefly, the universal fungal primers ITS4
(5’-TCC TCC GCT TAT TGA TAT GC-3’) and ITS86 (5’-GTG AAT CAT CGA ATC TTT
GAA C-3’) were used at a final concentration of 0.5 μM. Two μl of template DNA was added
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to a total volume of 10 μl LightCycler 480 HRMmaster mix (Roche, Basel, Switzerland).
Amplification was carried out on a LightCycler 480 (Roche) using the following program: pre-
incubation for 10 min at 95°C and amplification for 45 cycles of 20 s at 95°C, 30 s at 55°C and
30 s at 72°C, after which a high resolution melting curve was generated using the following pro-
tocol: 5 s at 95°C, 1 min at 60°C, followed by a gradual increase in temperature from 60°C to
97°C, using a ramp rate of 0.02°C per s, with one measurement per 2 s. Results were analyzed
with the standard LightCycler 480 Software, version 1.5 (Roche), as described previously [23].
It should be noted that the final sample volumes used for the direct and indirect methods
are not very much different between both methods: For culture, 10 μl of clinical sample is inoc-
ulated, such that, of an original presumptive 1000 cfu present in one ml of clinical sample, 10
would have been used for the culture approach.
For DNA extraction, 200 μl of clinical sample is used, which is finally eluted in 100 μl of elu-
tion buffer. Of this eluate, 2 μl is used in the qPCR, such that, of the original 1000 cfu present
in one ml, 4 would have been used for the PCR approach, which is only 2.5 times less than for
culture.
Results
During validation, the results showed that there was a perfect agreement between identification
with both methods, respectively MALDI-TOF and ITS2-HRM, for identification of the cul-
tured strains. Only MALDI-TOF based identification was used to validate the direct
ITS2-HRMmethod, because MALDI-TOF provides an independent identification approach
and because this approach is used in the routine bacteriology laboratory.
The detection limit of the direct approach ranged between 1.5 cells/μl (for C. dubliniensis)
and 55.6 cells/μl (for C. krusei), as determined on the basis of standard dilution series for each
of the 17 species studied (Table 1). Using these standard curves of the reference strains
(Table 1), optimized prior to analysis of clinical samples, quantification of the initial number of
yeast cells present was possible. During each run one dilution of each of the standard series of
C. albicans, C. glabrata, C. dubliniensis, C. parapsilosis and C. robusta was run along to serve as
reference melting peaks for correct identification of the most prevalent species. It should be
noted that quantification was not possible when two or more species were present simulta-
neously in the clinical sample.
Overall, the results of both the indirect and direct methods agreed in 83.9% of samples, with
52.8% that were negative with both methods, 25.6% that were positive for the same species,
5.2% that were positive for the same two species and one sample (0.3%) positive for the same
three species (Tables 2 and 3). From Table 2, sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) of the direct method can be calculated. A sensitivity
of 91.5%, a specificity of 80.8% and a NPV of 94.9% indicate that the direct method enables to
clearly distinguish between a positive and negative culture result. The direct method has a PPV
of 71.1%.
In the cases where two or more species are present simultaneously, one would expect multi-
ple peaks, each representing one of the species present in the clinical sample, as is the case for
e.g. the combination of C. guilliermondii and C. robusta (Fig 2a). However, in the case of the
simultaneous presence of C. albicans and C. glabrata (Fig 2b and 2c), only a subtle change in
the melting curve of the most abundant species indicates the presence of the other Candida
species. These findings in clinical samples led us to design an experiment in which various
ratios of C. albicans and C. glabrata were mixed and analyzed with ITS2-HRM, in order to
assess the impact on melting peak formation. Fig 3 illustrates the change in melting peak pat-
tern when the ratio between C. glabrata and C. albicans is experimentally varied. It showed
CandidaDetection from Clinical Samples
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that C. glabrata needs to be present to a much higher degree than C. albicans in order to be
observed as the main peak in the melting pattern (Fig 3a and 3b). But, even when C. glabrata is
present in a higher quantity relative to C. albicans, the mean peak in the pattern still results
from C. albicans. A ratio of 1 part of C. albicans to 4 parts of C. glabrata seems to be the limit
in order to detect the presence of C. glabrata in a mixed sample (Fig 3e). Its presence in this









Candida dubliniensis IHEM 14280 AF218993 289 1.52
C. nivariensis CBS 9983 KJ957824 396 1.81
C. metapsilosis CBS 10907 KP131737 261 1.87
C. parapsilosis ATCC 22019 AJ585347 257 2.08
C. lipolytica CBS 6660 AF218983 190 3.36
C. kefyr IHEM 04211 HE650694 378 5.33
C. guilliermondii IHEM 03283 AF218996 325 5.58
C. famata CBS 1795 AB696581 327 7.87
C. lusitaniae IHEM 10293 AF009215 205 11.4
C. albicans ATCC 90028 AF217609 284 12.8
C. orthopsilosis J 960161 HG970739 262 22.8
C. glabrata IHEM 04566 AF218994 365 23.6
C. norvegensis CBS 6564 AF333096 319 28.6
C. inconspicua HHR 0304
00305
KP131717 253 39.4
C. tropicalis IHEM 04222 HG970740 274 39.5
Saccharomyces cerevisiae (C.
robusta)
IHEM 14402 AF219006 366 40.0
C. krusei ATCC 06258 L47113 294 55.6
Legend: ATCC: American Type Culture Collection, Rockville, Maryland; IHEM: Institute for Hygiene & Epidemiology, Mycology, Brussels, Belgium; CS
Fungal Biodiversity Centre; J: non-CBS strains, obtained from CBS.
doi:10.1371/journal.pone.0132149.t001
Table 2. Comparison of the direct (ITS2-HRM) and indirect (culture/MALDI-TOF) method, expressed as percentage of samples relative to the total
number (347) of samples tested.
Indirect Total number
Positive Negative
Direct Positive 31.1% (TP) 12.7a % (FP) 152 71.1% (PPV)
Negative 2.9b % (FN) 53.3c % (TN) 195 94.9% (NPV)
Total number 118 229 347
91.5% (Sensitivity) 80.8% (Speciﬁcity)
Legend: TP: True positive; FP: False-positive; FN: False-negative; TN: True negative; PPV: positive predictive value, TP/(TP+FP); NPV: negative
predictive value, TN/(TN+FN); Sensitivity: TP/(TP+FN); Speciﬁcity: TN/(TN+FP)
a No species or less species than the number of species detected with the direct method. This category also contains one sample that was positive only
for Achromobacter xylosoxidans with the indirect method, while the direct method showed the presence of Candida albicans.
b No species or less species than the number of species detected with the indirect method
c Two of these samples were positive for Achromobacter xylosoxidans with the indirect method, but are counted as negative for Fungi.
doi:10.1371/journal.pone.0132149.t002
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situation was only indicated by the disappearance of the valley between the minor and the
major peak of Candida albicans.
Samples with both C. albicans and C. glabrata were observed a total of 20 times, of which 17
times by the direct and 15 times by the indirect method. For 12 of these 20 samples, both the
direct and the indirect method detected both species.
The most abundant species was C. albicans, present in 24.8% of all samples, and the second
most abundant species was C. glabrata (9.6% of all samples). Accordingly, the most frequent
type of samples containing two or more species comprised C. albicans and C. glabrata, and all
of them (4.9% of all samples) were from the IC ward (Table 3).
Interestingly, one sample contained Geotrichum silvicola, which was identified as such with
culture and MALDI-TOF (indirect method) and which resulted in a melting peak of 79.7°C
(direct method), not present in the Candida ITS2-HRM library. The same melting peak value
was obtained when performing ITS2-HRM on the cultured isolate, confirming the correct
identification when applying the direct method on the sample, and therefore the melting peak
value of this species was added to the library. Another interesting case was presented by a sam-
ple where three different species, namely C. kefyr, C. parapsilosis and Pichia manshurica, were
cultured and identified by MALDI-TOF. After ITS2-HRM, performed directly on the sample, a
melting curve pattern (Fig 4, solid line) was obtained which comprised six low intensity melt-
ing peaks. Although the melting peaks observed in the sample corresponded to the peaks that
could be obtained from the cultured isolates of the sample (Fig 4, dashed lines), direct
ITS2-HRM would not have yielded a sufficiently reliable identification in this situation.
Discrepancies were observed in 56 (i.e. 16.1%) of the samples, with two samples (S01 and
S54) representing two discrepancies, resulting in a total of 58 discrepancies. Most of the 58 dis-
crepancies could be considered as minor, because in most samples whereby one method
Table 3. Detailed overview of the results comparing the direct and indirect method, expressed as percentages for each of 5 types of samples.
Categories Throat (IC) Throat (H) Rectal (IC) Rectal (H) Vaginal (G) Total
Total number of samples 100 11 100 63 73 347
Negative with both methods (%) 25.0 72.7 55.0 61.9 76.7 52.8
Positive with both methods (1 species) (%) 41.0 9.1 26.0 12.7 17.8 25.6
Candida albicans 34.0 0.0 19.0 4.8 12.3 18.7
C. dubliniensis 3.0 0.0 1.0 0.0 1.4 1.4
C. glabrata 1.0 9.1 3.0 1.6 4.1 2.6
C. guilliermondii 0.0 0.0 0.0 1.6 0.0 0.3
C. parapsilosis 2.0 0.0 0.0 3.2 0.0 1.2
C. robusta 1.0 0.0 1.0 1.6 0.0 0.9
C. tropicalis 0.0 0.0 1.0 0.0 0.0 0.3
Geotrichum silvicola 0.0 0.0 1.0 0.0 0.0 0.3
Positive with both methods (2 or more species) (%) 12.0 0.0 6.0 1.6 0.0 5.5
C. albicans/C. dubliniensis 1.0 0.0 0.0 0.0 0.0 0.3
C. albicans/C. glabrata 7.0 0.0 5.0 0.0 0.0 3.5
C. glabrata/C. krusei 1.0 0.0 1.0 0.0 0.0 0.6
C. glabrata/C. lusitaniae 1.0 0.0 0.0 0.0 0.0 0.3
C. kefyr/C. parapsilosis/Pichia manshurica 0.0 0.0 0.0 1.6 0.0 0.3
C. parapsilosis/C. robusta 2.0 0.0 0.0 0.0 0.0 0.6
Discrepancies (%) 22.0 18.2 13.0 23.8 5.5 16.1
Legend: IC: Intensive Care, H: Haematology, G: Gynaecology.
doi:10.1371/journal.pone.0132149.t003
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detected more species than the other, this usually concerned species that were present in low
numbers. Twenty-one discrepancies were considered as major (see below), with 18 of these
major discrepancies (S21-S37 and S54) in the advantage of the direct method (Table 4).
Overall, the 58 discrepancies (in 56 samples) could be divided in the following 5 categories
(Table 4): Category A: direct method positive, but indirect method negative (n = 38); Category
B: direct method more species than indirect method (n = 6); Category C: direct method nega-
tive, but indirect method positive (n = 2); Category D: direct method less species than indirect
method (n = 9); and Category E: detection of nonfungal species by indirect method (n = 3).
The direct method discovered more species than the indirect method for 44 of the 56 sam-
ples with discrepant results (Table 4, column D> I).
Minor discrepancies were observed for 15 category A samples whereby C. albicans was
detected by the direct method (of which one sample (S12) also contained C. glabrata according
to the direct method), but not by the indirect method, because the number of cells/ml of sample
was determined by ITS2-HRM to be log 4.9 or lower in all of these samples. For the six category
B samples (S38-S43), two species were detected by the direct method, compared to only one by
the indirect method. The most abundant of both species (as determined on the basis of the
melting peak intensities) was also detected by the indirect method in five of these six cases
Fig 2. ITS2 High Resolution Melting Curve Analysis of clinical samples containing twoCandida species. The melting curve of the sample (solid line)
containing two species (according to culture results) is plotted against the melting curves of the standard strains (dotted curves) of the two respective
species.
doi:10.1371/journal.pone.0132149.g002
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Fig 3. Evaluation of the impact on the shape of the melting peak pattern by analyzing 5 different experimental ratios betweenCandida albicans and
C. glabrata, in which the latter one is respectively 250 (a), 200 (b), 100 (c), 10 (d) and 4 (e) fold more present.
doi:10.1371/journal.pone.0132149.g003
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(whereas the least abundant was detected by the indirect method in the sixth case), although
this resulted only in low numbers of colonies (between 1 and 30) for all six samples. Also these
six cases can be considered as minor discrepancies because the number of yeasts as estimated
by the direct method was also low, according to the high Cq values (which however could not
be converted to log values, because the samples contained more than one species). Another
minor discrepancy was presented by the only category C sample S44 for which only the indirect
method was positive for C. albicans, but whereby only 11 colonies were cultured. For the nine
category D samples (S45-S53), the direct method yielded only a single species, whereas the
indirect method yielded two (n = 7) or three (n = 2) species. Six of these nine cases could be
considered as minor discrepancies, because the one species that was missed by the direct
method was represented by only a low number of colonies in the indirect method. In the three
category E samples, the direct method remained negative (S55-S56) or yielded a low number of
C. albicans (S01), but the indirect method was positive. However, MALDI-TOF indicated that
in all three samples, the cultured organism was a bacterium, i.e. Achromobacter xylosoxidans.
This was considered as a minor discrepancy.
Another five samples (category A, S16-S20) comprised unknown melting peak patterns ver-
sus negative indirect method results (i.e. negative culture). Vaginal sample S16 had low inten-
sity melting peaks, not corresponding to any of the peaks in the library and sequencing yielded
Fig 4. Graphic display of the ITS2-HRM curve of the sample containingC. kefyr,C. parapsilosis and Pichia manshurica, according to culture.
ITS2-HRM patterns of strains of each species are added for comparison.
doi:10.1371/journal.pone.0132149.g004
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an unreliable identification (See below). The other four samples (S17-S20) had a combination
of peaks that was similar to the peaks observed when both C. glabrata and C. robusta were pres-
ent in the sample, but sequencing yielded no identification (due to mixed sequences). The
rather high Cq values indicated that the number of fungal cells present in all five of these sam-
ples was rather low, and was therefore considered a minor discrepancy.
The 21 major discrepancies comprised 18 category A samples (S21-S37: 14 rectal swabs and
four throat swabs, 13 from the haematology ward, five from the IC, and S54 (rectal swab,
hematology ward)), whereby the direct method detected the presence of C. robusta in relatively
high loads (between log4.39 and log7.51 cells/ml), whereas this species was missed by the indi-
rect method because the culture remained negative. For sample S54, culture yielded only two
Table 4. Detailed overview of the discrepancies, divided into following categories: Category A: direct method positive, but indirect method nega-
tive (n = 38); Category B: direct methodmore species than indirect method (n = 6); Category C: indirect method positive, but direct method nega-
tive (n = 2); Category D: indirect methodmore species than direct method (n = 9); and Category E: aspecific detection of nonfungal species by
indirect method (n = 3).
Category N° Discrepancy D > I a Sample ID Culture + N° ITS2-HRM pattern Concentration (Cq or log cells/ml)
A+E m+m 1 S01 ACHXYL 52 ALB 3.83
A m 13 S02-S11, S13-S15 N ALB 3.62–4.90
A m 1 S12 N ALB > GLA Cq 28.07
A m 1 S16 N ? b Cq 27.66
A m 4 S17-S20 N ? c Cq 26.84–28.39
A M 17 S21-S37 N ROB 4.39–7.51
B m 1 S38 ALB 1 ALB > GLA Cq 28.08
B m 1 S39 GLA 30 GLA > ALB Cq 24.97
B m 1 S40 GLA 3 GLA > ALB Cq 29.86
B m 1 S41 GUI 5 GUI > ROB Cq 26.45
B m 1 S42 GLA 4 GLA <? d Cq 26.13
B m 1 S43 GLA 4 ALB > GLA Cq 28.27
C m S44 ALB 11 N Below detection level
D M S45 ALB +++/DUB +++/GLA ++ ALB 8.09
D M S46 ALB +++/DUB +++/GLA +++ GLA 8.60
D M S47 ALB +++/GLA ++ ALB 8.35
D m S48 ALB +++/GLA 95 ALB 7.32
D m S49 ALB 187/GLA 3 ALB 7.23
D m S50 ALB +++/LUS 1 ALB 8.09
D m S51 ALB 108/ROB 1 ALB 6.63
D m S52 PAR +++/GUI 53 PAR 8.17
D m S53 ROB +++/PAR 74 ROB 9.39
A+C M+m 1 S54 TRO 2 ROB 6.83
E m S55-S56 ACHXYL +++ N Below detection level
Legend: ALB: Candida albicans; DUB: Candida dubliniensis; GLA: Candida glabrata; GUI: Candida guilliermondii; LUS: Candida lusitaniae; PAR: Candida
parapsilosis; ROB: Candida robusta; TRO: Candida tropicalis; ACHXYL: Achromobacter xylosoxidans; >: The left species is more abundant than the right
species; m: minor discrepancy; M: Major discrepancy; N: No species detected, below detection level; S: Sample; D: Direct method; I: Indirect method; +:
Indication of the quantity of a species, on the basis of number of colonies cultured;?: Unknown melting peak pattern.
a: Number of samples for which the direct method established the presence of more species than the indirect method (total number: 44).
b: Pattern of low intensity with unknown peak. Sequencing yielded an unreliable identiﬁcation (closest match Cladosporium cladosporioides).
c: Pattern of low intensity, similar to the pattern observed with a mixture of C. glabrata and C. robusta. Sequencing yielded an unreliable identiﬁcation
(closest match Physarum loratum).
d: Unknown peak at a Tm of 88.78°C
doi:10.1371/journal.pone.0132149.t004
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colonies of C. tropicalis. The identification of C. robusta based on the melting peak temperature
was confirmed for 12 cases by sequencing of the amplified ITS2 region. Apparently, C. robusta
(the anamorph of Saccharomyces cerevisiae), predominant in haematology samples (13 out of
74, compared to 5 out of 200 IC samples), is difficult to culture on Candida ID agar.
Major discrepancies were also present for three category D samples, whereby the indirect
method detected C. albicans and C. glabrata in large numbers, and in two of these three sam-
ples also C. dubliniensis, whereas the direct method indicated the presence of only C. albicans
(S45, S47) or only C. glabrata (S46).
In summary, there was full agreement in 83.90% of the 347 samples, minor discrepancy in
10.09% and major discrepancy in 6.01%, with most of these major discrepancies (18/21) due to
the lack of detection of C. robusta (S. cerevisiae) by the culture-based method (indirect
method).
The number of discrepancies for Haematology and IC departments and for throat and rectal
swabs were comparable (Tables 3 and 4). Only 5.5% (4 samples) of the 73 vaginal samples
resulted in outcomes that were discrepant between both methods, moreover considerable as
minor discrepancies. In three of these vaginal samples (S13-S15), C. albicans was found to be
present only by the direct method, but only in low amounts (between log3.95 and log4.28 cells/
ml). In one vaginal sample (S16), the direct method established, at only a low concentration
(Cq = 27.66), a low intensity melting peak pattern (not observed in any of the species present
in the library). Sequencing of the amplified ITS2 yielded only query cover of 62% to Cladospor-
ium cladosporoides.
Discussion
In this study, the efficacy of a molecular method (designated the ‘direct method’) to quantify
and identify the yeast species present in three types of clinical samples, i.e. throat swabs, rectal
and vaginal swabs, from three different departments was compared with the routine method
(the ‘indirect method’).
When the indirect method, i.e. culture of samples on Candida ID agar, followed by identifi-
cation of the colonies by means of MALDI-TOF, is taken as the reference method, the direct
method, consisting of DNA-extraction of the sample, followed by ITS2-qPCR and ITS2-HRM,
has a low positive predictive value. However, closer inspection of the observed discrepancies
(Table 4) indicates that most can be considered as minor. These minor discrepancies mostly
concern samples with low numbers of yeasts, as indicated by the high Ct-values of the qPCR,
whereby no yeasts could be cultured. Moreover, 18 of the 21 major discrepancies can be con-
sidered in the advantage of the direct method as well, because these concern samples that are—
strongly—positive for Candida robusta (the anamorph of Saccharomyces cerevisiae) by means
of the direct method, but negative by the indirect method, indicating that this species is missed
by culture on Candida ID agar. In intensive care unit patients, the probiotic use of Saccharomy-
ces cerevisiae has been documented to potentially lead to a fatal systemic disease [26–28]. The
ability of the direct method to detect and quantify the presence of this species might be consid-
ered as an additional advantage. Still, to control for false positive results due to contamination
from environment or during the DNA extraction procedure, simultaneous DNA extraction
from sterile water should be performed.
The most abundant species was C. albicans, present in 30.6% of all 111 throat swabs, 13.5%
of all 163 rectal swabs and 12.3% of all 73 vaginal samples. The second most abundant species
was C. glabrata in 2.6% of samples, most abundant in throat swabs of the haematology ward
(9.1% of all throat samples) and vaginal samples (4.1% of all vaginal samples). Accordingly, the
most frequent type of double positive samples comprised C. albicans and C. glabrata, and all of
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them (3.5% of all samples) were from the IC department, equally distributed between throat
and rectal swabs. Consequently, given the predominance of C. albicans and C. glabrata (and C.
robusta), the development of qPCR formats, specific for these species, instead of ITS2-HRM,
could be considered, to optimize the discriminative detection and quantification for samples
where both species are present.
The samples containing species such as Geotrichum silvicola and Pichia manshurica indicate
that ITS2-HRM also enables the detection of species of which no representative melting curves
were present in the original library. These species can be recognized by carrying out ITS2-HRM
on the cultured isolates that were identified by other means (e.g. MALDI-TOF) or—in case of
lack of a positive culture—by sequencing the ITS2 region that was amplified from the sample.
However, the latter approach is not possible when more than one species is present in the
sample.
The presence of yeast in a clinical sample was also examined through gram staining. Results
(data not presented) showed a correlation between the threshold cycle (Cq) and the detection
of yeast through microscopical analysis. The detection was possible in samples with a Cq lower
than 22, i.e. a yeast concentration of log6. Apparently, yeast present in concentrations below
log6 cfu/ml will be missed by Gram stain.
In conclusion, the direct method has some advantages over the indirect method, such as i)
speed (result possible within one day), ii) the possibility for more accurate quantification of the
number of yeasts present in the sample (by quantitative PCR), and iii) better sensitivity by
detecting also yeasts when present in low numbers, missed by culture, and by detection of Can-
dida robusta (missed by culture, also when present in large numbers). It remains to be decided
whether these putative advantages compensate for the disadvantages of this method, such as
the cost for consumables (especially due to the need for pure DNA-extraction when handling
clinical samples), estimated to amount to five times that of culture in combination with MAL-
DI-TOF, its laboriousness, and the lack of a cultured organism, needed to assess the antimyco-
tic susceptibility. However, the possibility offered by a molecular approach for rapid detection,
quantification and identification of yeasts from blood samples would certainly compensate for
the disadvantages of this approach.
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